ArticleBlood2016
The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- Beyond complement: comprehensive assessment of factor XIII plasma dynamics and genetics in atypical hemolytic uremic syndrome.Research and practice in thrombosis and haemostasis · 2026Article
- SARS-CoV-2 spike protein can bind fibrin(ogen), but does not alter plasma fibrin formation, clot structure, or lysis.Blood advances · 2026Article
- Targeting the Primordial Chaperone to Overcome Acquired Drug Resistance in Cancer: TG2-Mediated Autophagy.Biomolecules & therapeutics · 2026Review
- Review
- Another cryo-EM success: structure of FXIII.Blood · 2025Article
- Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients.Research and practice in thrombosis and haemostasis · 2025Article
- Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation.Blood advances · 2024Article
- Coagulation factor XIII is a critical driver of liver regeneration after partial hepatectomy.Journal of thrombosis and haemostasis : JTH · 2024Article
- Article
- Fibrinogen and fibrin: synthesis, structure, and function in health and disease.Journal of thrombosis and haemostasis : JTH · 2023Review
- The role of fibrinogen in traumatic brain injury: from molecular pathological mechanisms to clinical management.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2023Review
- Mathematical modeling to understand the role of bivalent thrombin-fibrin binding during polymerization.PLoS computational biology · 2022Article
- Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.Arteriosclerosis, thrombosis, and vascular biology · 2022Review
- Novel interaction of properdin and coagulation factor XI: Crosstalk between complement and coagulation.Research and practice in thrombosis and haemostasis · 2022Article
- Factor XIII is a newly identified binding partner for platelet collagen receptor GPVI-dimer-An interaction that may modulate fibrin crosslinking.Research and practice in thrombosis and haemostasis · 2022Article
- Article
- Functional and Structural Characterization of Nucleic Acid Ligands That Bind to Activated Coagulation Factor XIII.Journal of clinical medicine · 2021Article
- Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism.International journal of molecular sciences · 2021Review
- Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- The Structure of Blood Coagulation Factor XIII Is Adapted to Oxidation.Biomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
James R ByrnesDepartment of Pathology and Laboratory Medicine and McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Clare WilsonDivision of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine, Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds, United Kingdom; and.
Anthony M BoutelleDepartment of Pathology and Laboratory Medicine and McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Chase B BrandnerDepartment of Pathology and Laboratory Medicine and McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Matthew J FlickDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH.
Helen PhilippouDivision of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine, Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds, United Kingdom; and.ORCID 0000-0002-9199-4201
Alisa S WolbergDepartment of Pathology and Laboratory Medicine and McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-2845-2303
University of North Carolina at Chapel Hill · USUniversity of Leeds · GBCincinnati Children's Hospital Medical Center · US
Funding
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6MNorth Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9MFibrinogen and Factor XIII in Venous ThrombosisR01HL126974 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Alisa S. Wolberg · 2016 to 2026
$4.4MHemostatic factors and sickle cell diseaseR01HL112603 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI FLICK, MATTHEW J., MALIK, PUNAM · 2012 to 2016
$1.9MDeterminants of Thrombus Structure and StabilityR56HL094740 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLBERG, ALISA S. · 2014 to 2014
$378kBritish Heart Foundation PG/08/052/25172British Heart Foundation SP/12/11/29786British Heart Foundation SP/14/1/30717NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR002489NHLBI NIH HHS R01 HL112603NHLBI NIH HHS R01 HL126974NHLBI NIH HHS R56 HL094740
Abstract
Coagulation transglutaminase factor XIII (FXIII) exists in circulation as heterotetrameric proenzyme FXIII-A
Indexed as
Enzyme PrecursorsFactor XIIIFibronectinsAmino Acid MotifsAnimalsHumansMiceMice, KnockoutProtein BindingRecombinant ProteinsSurface Plasmon ResonanceEnzyme PrecursorsFactor XIIIfactor XIIIbfactor XIII subunit AFibronectinsRecombinant Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.